Compare SDHC & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SDHC | KZIA |
|---|---|---|
| Founded | 2008 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.3M | 100.8M |
| IPO Year | 2023 | 2002 |
| Metric | SDHC | KZIA |
|---|---|---|
| Price | $13.16 | $13.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $14.60 | ★ $19.50 |
| AVG Volume (30 Days) | 77.6K | ★ 274.9K |
| Earning Date | 04-29-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $971,116,000.00 | N/A |
| Revenue This Year | $4.21 | N/A |
| Revenue Next Year | $11.07 | N/A |
| P/E Ratio | $216.67 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.13 | $3.05 |
| 52 Week High | $23.50 | $17.40 |
| Indicator | SDHC | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 43.05 | 72.60 |
| Support Level | $11.18 | $5.85 |
| Resistance Level | $15.45 | $14.42 |
| Average True Range (ATR) | 0.90 | 1.23 |
| MACD | -0.13 | 0.16 |
| Stochastic Oscillator | 16.37 | 89.23 |
Smith Douglas Homes Corpis a builder of single-family homes in communities in certain markets in the southeastern and southern United States. The Company's homes and communities are targeted to first-time and empty-nest homebuyers. The Company currently operates in metropolitan Atlanta, Birmingham, Chattanooga, Central Georgia, Charlotte, Dallas-Fort Worth, Greenville, Alabama Gulf Coast, Huntsville, Nashville, Raleigh and Houston. Its operations are currently organized into ten geographical divisions which comprise two reportable segments. Its Southeast segment consists of its Atlanta, Central Georgia, Charlotte, Greenville, and Raleigh divisions. Its Central segment consists of its Alabama, Dallas-Fort Worth, Houston, Nashville, and Alabama Gulf Coast divisions.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.